ProstaScint capromab pendetide: Marketed

In a retrospective study of 142 prostate cancer patients, CYTO said that

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE